You are here

  • Home
  • Archive
  • Volume 33, Issue 11
  • Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions

Citation Tools

Article menu

Download PDFPDF

Original research
Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Herzog TJ, Wahab SA, Mirza MR, et al
Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions
International Journal of Gynecologic Cancer 2023;33:1733-1742.